Fulcrum Therapeutics (FULC) Preferred Stock Liabilities (2018 - 2019)
Fulcrum Therapeutics (FULC) reported Preferred Stock Liabilities of $105.2 million for Q2 2019, up 75.64% year-over-year from $59.9 million in Q2 2018, and up 75.64% quarter-over-quarter from $59.9 million in Q1 2019.
Fulcrum Therapeutics (FULC) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Fulcrum Therapeutics (FULC) has 2 years of Preferred Stock Liabilities data on file, last reported at $105.2 million in Q2 2019.
- Preferred Stock Liabilities for Q2 2019 came in at $105.2 million, up 75.64% year-over-year; the trailing twelve-month figure through Jun 2019 was $105.2 million (up 75.64% YoY), and the FY2018 annual result was $79.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities advanced to $105.2 million in Q2 2019 per FULC's latest filing, from $59.9 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $105.2 million in Q2 2019 and troughed at $59.9 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 105.23 Mn |
| Mar 31, 2019 | 59.91 Mn |
| Dec 31, 2018 | 79.76 Mn |
| Sep 30, 2018 | 59.91 Mn |
| Jun 30, 2018 | 59.91 Mn |